title: Overexpression of CD151 predicts prognosis in patients with resected gastric cancer.
abstract: OBJECTIVE
  The tetraspanin CD151 acts as a promoter of metastasis and invasion in several tumors. However, the role of CD151 in human gastric cancer (HGC) remains unclear.
  
  
  METHODS
  Twenty HGC specimens and matched nontumor samples, human gastric epithelial cells (HGEC), and four gastric cancer cell lines were used to analyze CD151 expression. Short hairpin RNA-mediated downregulation of CD151 expression in HGC cells was performed to examine the role of CD151 in the proliferation and metastasis/invasion of HGC cells in vivo and in vitro. The relationship of CD151 with integrin α3 in HGC cells was investigated by silencing integrin α3 followed by co-immunoprecipitation and immunofluorescence staining. Finally, the prognostic value of CD151 and integrin α3 was evaluated by immunohistochemistry in tissue microarrays of 76 HGC patients.
  
  
  RESULTS
  CD151 was expressed at higher levels in HGC tissues and HGC cells than in nontumor tissues and HGEC cells. Down-regulation of CD151 by vshRNA-CD151 impaired metastasis and invasion of HGC-27 cells, but did not affect cell proliferation. CD151 formed a complex with integrin α3 in HGC cells. CD151-cDNA transfection rescued the metastatic potential and invasiveness of HGC-27-vshCD151 cells, but not those of HGC-27-vshintegrin α3 cells in vitro. Clinically, CD151 overexpression was significantly correlated with high TNM stage, depth of invasion and positive lymph node involvement (p<0.05), and high levels of integrin α3 were associated with large tumor size, high TNM stage, depth of invasion and lymph node involvement (p<0.05). Importantly, the postoperative 5-year overall survival of patients with CD151(low) and/or integrin α3(low) was higher than that of patients with CD151(high) and/or integrin α3(high).
  
  
  CONCLUSIONS
  CD151 is positively associated with the invasiveness of HGC, and CD151 or the combination of CD151 and integrin α3 is a novel marker for predicting the prognosis of HGC patients and may be potential therapeutic targets.
authors.affiliation: Department of Gastrointestinal Surgery, Shaoxing Hospital of First Affiliated Hospital of Medical School of Zhejiang University, Shaoxing, PR China. ymyang55@163.com
authors.forename: Yue-Ming
authors.initials: YM
authors.lastname: Yang
authors.forename: Zhong-Wei
authors.initials: ZW
authors.lastname: Zhang
authors.forename: Qing-Meng
authors.initials: QM
authors.lastname: Liu
authors.forename: Yi-Feng
authors.initials: YF
authors.lastname: Sun
authors.forename: Ji-Ren
authors.initials: JR
authors.lastname: Yu
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Xu
mesh_terms: D000368:Aged; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D015151:Immunoblotting; D047468:Immunoprecipitation; D066298:In Vitro Techniques; D039422:Integrin alpha3 / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011485:Protein Binding; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D060185:Tetraspanin 24 / Q000235:genetics / Q000378:metabolism*
chemical_list: D039422:Integrin alpha3; D060185:Tetraspanin 24